Samantha Fredman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Samantha Fredman has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Amanda Debuo Der
School of Public Health, University of Ghana – Legon, Accra, Ghana
1 shared publication - Anna E. Fiastro
Department of Family Medicine, University of Washington, Seattle, Washington
1 shared publication Bhavatharini Kasinathan
1 shared publicationDanelle Hidano
1 shared publicationElissa M. Brown
1 shared publicationEmily M. Godfrey
1 shared publication
Latest Publications
- Open Access
- 24 September 2026
- Published by Springer Nature in Research Square
Publicly Funded Systems Utilization in the Context of Combined Pharmacobehavioral Harm Reduction Treatment for People with Lived Experience of Homelessness and Hazardous Drinking
Harm reduction treatment for alcohol (HaRT-A) reduces alcohol-related harm and improves health-related quality of life (HRQoL) without requiring abstinence. HaRT-A is efficacious alone and with extended-release naltrexone (XR-NTX) for people experiencing homelessness and alcohol use disorder (AUD). This study extended analyses from a prior randomized controlled trial (RCT) to test HaRT-A effects on jail and healthcare costs. Exploratory analyses tested baseline sociodemographic, HRQoL and substance-use variables as predictors of system utilization. RCT participants experienced homelessness and AUD (N=308). They were randomized to 12 weeks of HaRT-A plus XR-NTX, HaRT-A plus placebo, HaRT-A alone, or services-as-usual control. Baseline sociodemographics, HRQoL, and substance-use data were assessed with single-items on self-report measures. Use and cost of emergency medical services (EMS), emergency department, hospitalizations, and jail were extracted from administrative records. Exploratory analyses included a larger screened sample of people with lived experience of homelessness and hazardous drinking (N=401). There were no significant HaRT-A or XR-NTX effects on costs ( p s>.05). Exploratory analyses showed age was inversely correlated with EMS use (IRR=0.97, p=0.002). Smoking (IRR=2.02, p=0.03) and alcohol-related harm (IRR=1.04, p=0.005) were associated with more jail bookings. Less alcohol use (IRR=0.94, p=0.02), greater alcohol-related harm (IRR=1.06, p=0.01), and higher mental-health QoL (IRR=1.13, p=0.04) were associated with more jail days. Lack of HaRT-A and XR-NTX effects on costs may reflect low power, brief follow-up period, and the treatment's brevity. Studies testing longer-term HaRT-A + XR-NTX may provide a stronger test of its potential to reduce costs. Exploratory analyses provide points for potential intervention.
- 24 September 2026
- Published by Springer Nature in Research Square
Open AccessPublicly Funded Systems Utilization in the Context of Combined Pharmacobehavioral Harm Reduction Treatment for People with Lived Experience of Homelessness and Hazardous Drinking
Harm reduction treatment for alcohol (HaRT-A) reduces alcohol-related harm and improves health-related quality of life (HRQoL) without requiring abstinence. HaRT-A is efficacious alone and with extended-release naltrexone (XR-NTX) for people experiencing homelessness and alcohol use disorder (AUD). This study extended analyses from a prior randomized controlled trial (RCT) to test HaRT-A effects on jail and healthcare costs. Exploratory analyses tested baseline sociodemographic, HRQoL and substance-use variables as predictors of system utilization. RCT participants experienced homelessness and AUD (N=308). They were randomized to 12 weeks of HaRT-A plus XR-NTX, HaRT-A plus placebo, HaRT-A alone, or services-as-usual control. Baseline sociodemographics, HRQoL, and substance-use data were assessed with single-items on self-report measures. Use and cost of emergency medical services (EMS), emergency department, hospitalizations, and jail were extracted from administrative records. Exploratory analyses included a larger screened sample of people with lived experience of homelessness and hazardous drinking (N=401). There were no significant HaRT-A or XR-NTX effects on costs ( p s>.05). Exploratory analyses showed age was inversely correlated with EMS use (IRR=0.97, p=0.002). Smoking (IRR=2.02, p=0.03) and alcohol-related harm (IRR=1.04, p=0.005) were associated with more jail bookings. Less alcohol use (IRR=0.94, p=0.02), greater alcohol-related harm (IRR=1.06, p=0.01), and higher mental-health QoL (IRR=1.13, p=0.04) were associated with more jail days. Lack of HaRT-A and XR-NTX effects on costs may reflect low power, brief follow-up period, and the treatment's brevity. Studies testing longer-term HaRT-A + XR-NTX may provide a stronger test of its potential to reduce costs. Exploratory analyses provide points for potential intervention.